Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment-Reference-Cited by-同舟云学术

Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment

Published:2016-03-25 Issue:4 Volume:8 Page:91
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Bagaglio Sabrina,Andolina Andrea,Merli Marco,Uberti-Foppa Caterina,Morsica Giulia

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Link

http://www.mdpi.com/1999-4915/8/4/91/pdf

Reference20 articles.

1. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

2. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

3. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

4. Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

5. Antiviral activity and resistance of HCV NS5A replication complex inhibitors

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy;International Journal of Molecular Sciences;2023-12-22

2. Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review;Frontiers in Immunology;2023-03-31

3. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents;Clinical Gastroenterology and Hepatology;2021-09

4. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection;Frontiers in Microbiology;2021-01-28

5. Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C;Biomedicines;2020-04-07